Cardiovascular outcome trials revealed that SGLT2 inhibition among patients with type 2 diabetes reduced the risk of cardiovascular events, cardiovascular mortality, and all-cause mortality, with consistency of favorable heart failure and kidney outcomes across the drug class [5, 6]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.